Chief Medical Officer
Peptomyc, S.L., Spain
Dr Niewel is an MD educated oncologist, who has focused nearly her entire career within the Oncology space, from first in men through registration of oncology drugs. She has expertise and experience in Translational Medicine, Clinical Research and Medical Affairs. She started as a resident within Oncology hospitals (medical oncology as well as radiation therapy) in Germany, being responsible for the treatment of cancer patients. She then moved into the industry to focus her work within the Clinical Development setting. She joins Peptomyc from Rigontec, a start-up biotech acquired by Merck Sharp & Dohme, where she served as Senior Vice President for Clinical Development since 2015, bringing their compound very quickly and successfully into the clinic. Dr. Niewel also acted as a clinical development consultant for several biotech companies and held Senior Medical Director positions at several global CROs, and led Clinical Research groups at different Pharma- and Biotech companies. She obtained her M.D. diploma and doctoral degree at the University Munich and her Diploma in Pharmaceutical Medicine at DGPharMed Munich, Germany.
